Clinical Trial Update: Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL [Phase 2]

View source ↗

Summary

A Phase 2 study assessing cladribine and rituximab as induction therapy, followed by rituximab and stem cell mobilization in patients with chronic lymphocytic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Cladribine (cladribine)
• Rituximab (rituximab)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Leukemia | Phase 2 | Status: COMPLETED